#PARP Inhibitor Market

[cmisushil]

PARP Inhibitos have emerged as potent warriors in the battle against DNA damage. Our DNA is constantly under assault from various sources, including environmental factors and endogenous processes

Read More:

https://bloggers-vision.blogspot.com/2023/06/unleashing-power-of-parp-inhibitor.html

[mrunalnerkarblog]

Poly ADP-Ribose Polymerase (PARP) inhibitors are long chain containing 17 enzymes that combine several (poly) units of ADP-ribose in a chain and transfer them to the target proteins. This helps to restore DNA when it is damaged by many factors such as exposure to UV  radiation, some anti-cancer drugs and others. PARP inhibitors block an enzyme critical to the repair of single stranded breaks in the DNA. Inhibition of this DNA repair enzyme can lead to cell death, particularly in cancer cells that carry deficiency of other DNA repair pathways.

[marketsandatablog]

Global PARP inhibitors market is projected to witness a CAGR of 13.31% during the forecast period 2024-2031, growing from USD 6.44 billion in 2023 to USD 17.5 billion in 2031F. Increased investments in research and development activities and the increasing prevalence of cancer are providing lucrative growth opportunities to the market.

[healthcaredbmrnews]

https://www.databridgemarketresearch.com/reports/global-poly-adp-ribose-polymerase-parp-inhibitors-market

[hrishikeshqmi]

Global PARP Inhibitor Market To Grow At A CAGR Of 27.4% Due To Expanding Role Of PARP Inhibitors In Cancer Treatment

[thesunshinereporter]

PARP Inhibitor Biomarkers Market Report On The Untapped Growth Opportunities In The Industry

http://dlvr.it/T6qb1L

[biotech-news-feed]

Back in 2014, AstraZeneca and Merck were the first to receive FDA approval for their PARP inhibitor Lynparza (olaparib) for use in breast cancer gene (BRCA)-mutated metastatic ovarian cancer patients. #BioTech #science

[health-views-updates]

Breast Cancer Therapeutics Market Research Report Analysis and Forecasts to 2031

The breast cancer therapeutics market has been on a trajectory of significant growth in recent years, driven by advancements in treatment modalities, increasing awareness, and rising incidence of breast cancer worldwide. According to recent market analysis, the global breast cancer therapeutics market size was valued at USD 30.22 billion in 2022, and it is projected to reach USD 79.77 billion by 2030, growing at a remarkable compound annual growth rate (CAGR) of 12.9% over the forecast period of 2023-2030.

Report Scope

This report provides a comprehensive analysis of the breast cancer therapeutics market, encompassing factors such as market size, growth drivers, challenges, regional analysis, and key developments. It offers insights into the current market dynamics and future growth prospects, equipping stakeholders with actionable intelligence to make informed decisions.

Market Analysis

The growth of the breast cancer therapeutics market can be attributed to several factors, including the increasing prevalence of breast cancer globally, advancements in treatment options such as targeted therapies and immunotherapies, and growing investments in research and development. Additionally, rising awareness about early detection and diagnosis, coupled with government initiatives and advocacy programs, has contributed to improved treatment outcomes and increased adoption of breast cancer therapeutics.

Download Free Sample Report: https://www.snsinsider.com/sample-request/2943

Impact of the Russia-Ukraine Conflict

The ongoing conflict between Russia and Ukraine has raised concerns about its potential impact on the pharmaceutical industry, including disruptions in the supply chain and fluctuations in raw material prices. While the full extent of the impact remains uncertain, heightened geopolitical tensions could lead to delays in drug development and distribution, affecting the breast cancer therapeutics market and other sectors of the healthcare industry.

The Impact of Economic Slowdown

Economic slowdowns, exacerbated by factors such as the COVID-19 pandemic, can have a significant impact on healthcare spending and investment in research and development. A downturn in the economy may lead to budget constraints for healthcare systems and reduced access to innovative breast cancer therapies for patients. However, despite economic challenges, the growing burden of breast cancer and the imperative to improve patient outcomes are likely to sustain demand for therapeutics in the long term.

Regional Analysis

The breast cancer therapeutics market exhibits regional variations influenced by factors such as healthcare infrastructure, regulatory frameworks, and socio-economic factors. North America and Europe dominate the market, driven by robust healthcare systems, high prevalence of breast cancer, and early adoption of advanced therapies. Meanwhile, Asia-Pacific presents lucrative growth opportunities, fueled by increasing healthcare expenditure, rising awareness, and improving access to healthcare services.

Key Takeaways and Recent Developments

In conclusion, the breast cancer therapeutics market is poised for significant growth, driven by factors such as technological advancements, increasing incidence of breast cancer, and expanding treatment options. Key takeaways include the importance of early detection and diagnosis, the role of targeted therapies in improving patient outcomes, and the potential impact of geopolitical and economic factors on market dynamics.

Recent developments in the breast cancer therapeutics market include the emergence of novel treatment modalities such as PARP inhibitors, CDK4/6 inhibitors, and immune checkpoint inhibitors, offering new hope for patients with advanced or metastatic breast cancer. Additionally, ongoing research efforts focused on biomarker-driven therapies and combination strategies hold promise for further advancements in breast cancer treatment.

As stakeholders navigate the evolving landscape of the breast cancer therapeutics market, strategic investments in research and development, partnerships, and patient-centric approaches will be crucial to driving innovation and improving outcomes for patients affected by this devastating disease.

[mrunalnerkarblog]

PARP are poly(adenosine diphosphate [ADP] -ribose) polymerase. It is a group of 17 enzymes that combine several (poly) units of ADP-ribose in a chain and transfer them to the target proteins. Poly(ADP-ribose) polymerase (PARP) inhibitor plays a vital role in the repair of single-strand DNA. PARP inhibitors are thought to become trapped at the sites of single-strand DNA breaks leading to double-strand DNA breaks when DNA replication is attempted. The double-strand DNA breaks would normally be repaired by the process of homologous recombination repair (HRR), which is a complex process including many proteins, notably BRCA1 and BRCA2 which are also known as biomarkers of PARP inhibitors.

[iebpharma]

Olakin 150mg (Olaparib) | Order Now At IEB Pharma

Olakin 150mg, also known as Olaparib, is a medication belonging to the class of drugs called PARP inhibitors. Developed and marketed by AstraZeneca, Olaparib has gained significant attention in the medical community for its efficacy in treating certain types of cancer, particularly ovarian and breast cancers. In this comprehensive overview, we will delve into the mechanism of action, indications, dosage, side effects, and recent advancements related to Olakin 150mg.

Mechanism of Action:

Olaparib works by inhibiting the enzyme poly ADP-ribose polymerase (PARP). PARP is involved in the repair of damaged DNA in cells. By inhibiting PARP, Olaparib prevents cancer cells from repairing their damaged DNA, ultimately leading to their death. This mechanism is particularly effective in cancer cells that already have impaired DNA repair mechanisms, such as those with mutations in BRCA genes.

Indications:

Olaparib is primarily indicated for the treatment of advanced ovarian cancer and metastatic breast cancer in patients with mutations in BRCA1 or BRCA2 genes. Additionally, it has shown promising results in other types of cancer, including prostate cancer and pancreatic cancer, especially in patients with BRCA mutations or other DNA repair deficiencies.

Dosage:

The recommended dosage of Olakin 150mg (Olaparib) may vary depending on the type of cancer being treated, the patient's overall health, and other medications they may be taking. It is typically administered orally in the form of tablets and is usually taken once or twice daily with or without food. The dosage should be determined by a healthcare professional based on individual patient factors.

Side Effects:

Like any medication, Olaparib can cause side effects, although not everyone experiences them. Common side effects may include nausea, vomiting, diarrhea, fatigue, loss of appetite, headache, and anemia. More serious side effects such as bone marrow suppression, which can lead to an increased risk of infection or bleeding, may also occur but are less common. Patients should report any persistent or severe side effects to their healthcare provider promptly.

Recent Advancements:

In recent years, research on Olaparib has expanded beyond its initial indications. Studies have explored its efficacy in combination with other cancer treatments, such as chemotherapy and immunotherapy, as well as its potential for use in earlier stages of cancer treatment. Additionally, ongoing clinical trials are investigating Olaparib's effectiveness in various cancer types and patient populations, including those without BRCA mutations.

Conclusion:

In conclusion, Olakin 150mg (Olaparib) represents a significant advancement in the treatment of certain types of cancer, particularly ovarian and breast cancers with BRCA mutations. Its unique mechanism of action, coupled with ongoing research and clinical trials, holds promise for improving outcomes for cancer patients in the future. However, it is essential for healthcare providers to closely monitor patients receiving Olaparib for potential side effects and adjust treatment as needed to ensure optimal safety and efficacy.

[healthcaretechnologynews]

GRG Health Competitive Intelligence (CI) Perspectives and Opinions, October 2022

The development:

In October 2022, Dostarlimab met its primary endpoint of Objective Response Rate (ORR) in a head-to-head trial against Pembrolizumab (KEYTRUDA, Merck) in NSCLC (vide PERLA trial – a global, randomized, double-blind phase II trial of 243 patients).

Write to us at enquire@grgonline.com Learn how GRG Health is helping clients gather more in-depth market-level information on such topics.

Opening thoughts:

Dostarlimab – an asset that GlaxoSmithKline (GSK) obtained by acquiring Tesaro, is proving dependable in sundry trials.

This is probably a blessing since the GSK – Tesaro transaction has had more than its fair share of headlines….and the price tag (USD5.1 billion) was not even at the top of that list!

However, a lot more must be done by GSK to ensure smooth sailing.

Thankfully, Dostarlimab -gxly injection (TSR-042, brand name JEMPERLI) is a key asset that has always remained in the spotlight, mostly for the right reasons.

Asset Outline: 

Profile – Dostarlimab-gxly injection (TSR-042, brand name JEMPERLI) is a humanized monoclonal antibody (IgG4 isotype) PD-1 inhibitor that targets the mismatch repair deficiency mutation (dMMR). Dostarlimab is particularly interesting since the dMMR mutation occurs in multiple indications (including breast, endometrial, uterine, prostate, rectal). Besides, dMMR tumors may also develop Microsatellite Instability (or MSI)

Potential – Dostarlimab’s potential is believed to be high; the asset was a healthy influencer (besides the oral PARP inhibitor Niraparib (brand name Zejula) and the TIM-3 mAb Cobolimab) that drove GSK to acquire Tesaro.

Performance – Since 2021, Dostarlimab is approved across the EU and the United States for recurrent or primary advanced dMMR endometrial cancer that has progressed on or following prior therapy with a Platinum-containing regimen. The initial approval was granted based on preliminary results vide GARNET trial or NCT02715284 since indication – specific therapies were unavailable for patients.

Asset Spotlight:

Past achievement – Dostarlimab was in further trials when it took centerstage (worldwide) in July/August 2022

o Claim to fame – Dostarlimab took centerstage because of its celebrated, outstanding results (100% remission of disease) in a subgroup of patients who had dMMR rectal cancer (all either Stage II or III disease)

o Claim specs – The study conducted at Memorial Sloan Kettering Cancer Center (MSKCC), New York (United States), intravenously dosed these patients with Dostarlimab every three weeks for a duration of six months

Relevance – Since the current SOC for rectal cancer is neoadjuvant Chemoradiotherapy (CRT) followed by Surgery and adjuvant chemotherapy, the celebration for Dostarlimab’s performance is understandable.

Recent achievement – In October 2022, Dostarlimab announced a landmark in NSCLC.

o Claim to fame – Dostarlimab met its primary endpoint (ORR) in NSCLC (vide Open label, Double blind PERLA trial)

o Claim specs – The study put Dostralimab head-to-head against Pembrolizumab (KEYTRUDA, Merck)

Relevance – Since Dostarlimab went head-to-head against KEYTRUDA which is widely regarded as a top intervention, evaluating Dostarlimab’s performance in detail is likely to establish its standing as one more promising option and/or a challenger.

Next steps – Hopefully, future data will show not just ORR but survival benefit too. This would help to clarify the extent of Dostarlimab’s advantage in a key indication vis-à-vis an established gamechanger (KEYTRUDA).

This is going to be relevant since ORR alone might not be accurately reflecting survival advantage.

The CI angle:

What generates interest –

o PERLA: GSK already has Zejula (which competes with the better – established LYNPARAZA, Astra Zeneca) in pharmacies. Now, with Dostarlimab meeting its primary endpoint in PERLA and progressing further in the COSTAR Lung trial - comprising patients with advanced NSCLC who progressed in spite of prior anti-PD-L1 therapy and chemotherapy, GSK’s future as an oncology player looks promising, currently.

What generates anxiety –

o dMMR Rectal cancer:

Trial span: The widely lauded rectal cancer study was constrained by the (low) number of patients and a single trial institution.

Durability of response: Evidence of durable response can emerge after these patients are followed for at least three years to assess (the absence of) recurrence.

Price point (and affordability): Given the trial results (and the cost of Tesaro’s acquisition), Dostarlimab is likely to be available at a steep price

Ø Reportedly, the nine doses of Dostarlimab that are required over a six-month period cost USD99,000 (INR 77 lakh). Such a price tag will adversely affect uptake, especially in the third world where future disease burden is likely to surpass the first world

Ø Further, third world markets are likely to be characterized by late diagnosis (poor prognosis), low per capita income, and poor penetration of insurance

o NSCLC:

The PERLA study included first-line patients (N = 243) with metastatic nonsquamous NSCLC and no known sensitizing EGFR, ALK or receptor tyrosine kinase-1 mutation, BRAF V600E mutation, or other genomic mutation for which an approved targeted therapy is available. How this affects Dostarlimab’s promise remains to be seen especially since the phase 2 PERLA study is not likely to enable any drug applications. Further, development plans for Dostarlimab in frontline NSCLC remain unclear

o Self-sufficiency:

Tesaro reportedly developed Zejula by licensing Astra Zeneca’s technology platform! This is not unusual in the industry but how it will affect Dostarlimab, GSK’s oncology outlook, and GSK’s tech-specific self-sufficiency remains to be seen

Closing Opinion:

The Tesaro portfolio is proving useful for GSK, representing promise in the medium term. However, all assets report a subset-specific disease focus besides lacking synergies with established interventions.

GRG Health’s CI engagements have also revealed that there is a lack of adequate awareness and engagement even for proven assets like ZEJULA. This is concerning.

Further, GSK seems to lack a coherent strategy ever since the loss of its Respiratory assets – it would be worrying if an erstwhile, established leader in respiratory diseases relies more on M&A than either organic evolution or balanced development for the way forward.

The collective effect of such concerns is probably reflected in the consistently low share price of GSK.

In view of the above and the potential crowding of the PD-1/L1 space, GSK should aggressively focus on generating robust, broad-based data across indications to firmly establish its portfolio in oncology at the earliest.

Visit our website now: https://www.grgonline.com/

[informationtechnology0101]

Revolutionizing the Ovarian Cancer Market: Strategies for Success | DLI

Ovarian Cancer Overview:

Ovarian Cancer is a formidable health challenge affecting women globally. It is characterized by the abnormal growth of cells in the ovaries, which are vital components of the female reproductive system. Often diagnosed at an advanced stage, ovarian cancer poses significant clinical and therapeutic complexities.

Ovarian cancer silently appears as a powerful foe that demands undivided attention. It is unyielding and resilient. It affects women of all ages and socioeconomic backgrounds and spares no one. This sneaky illness hides its presence, frequently coming to light only when the fight grows more difficult.

The Market Competitors Listed Below are Revolutionizing Healthcare with Innovative Diagnostic Inventions:

Price & Market Access

Diagnostic Analysis:

Early Detection Challenges:

Early diagnosis of ovarian cancer remains a critical issue due to its asymptomatic nature in the initial stages. Lack of specific symptoms and effective screening tools makes timely detection a formidable task.

Screening Methods:

Currently, screening methods primarily include pelvic examinations, transvaginal ultrasounds, and blood tests measuring CA-125 levels. However, these methods often lack the sensitivity and specificity needed for reliable early detection.

Treatment Analysis:

Standard Treatment Modalities:

Treatment approaches for ovarian cancer encompass a multidisciplinary approach, including surgery, chemotherapy, radiation therapy, and targeted therapy. The extent of surgical intervention and choice of chemotherapeutic agents are determined by factors like stage, histology, and patient's overall health.

Emerging Therapies:

Immunotherapy and personalized medicine are emerging as promising avenues in ovarian cancer treatment. These approaches aim to enhance the body's natural immune response and tailor treatments based on the genetic profile of the tumor.

Regulatory Framework:

FDA and EMA Guidelines:

Regulatory bodies like the FDA (Food and Drug Administration) in the United States and EMA (European Medicines Agency) in Europe play a pivotal role in approving and regulating treatments for ovarian cancer. Rigorous clinical trials and safety assessments are mandatory before a therapy can be marketed.

Therapeutics:

Targeted Therapies:

Targeted therapies like PARP inhibitors and angiogenesis inhibitors have shown promise in treating specific types of ovarian cancer. They work by interfering with the specific molecular pathways that cancer cells rely on for growth.

Immunotherapies:

Immunotherapies, including checkpoint inhibitors, are being investigated for their potential to enhance the body's immune system to recognize and attack ovarian cancer cells.

Diagnostic Techniques:

Genomic Profiling:

Advancements in genomic profiling have revolutionized the understanding of ovarian cancer. DNA sequencing and molecular profiling enable a more precise characterization of the tumor, guiding treatment decisions.

Liquid Biopsies:

Liquid biopsies, analyzing blood or other bodily fluids, offer a non-invasive method to monitor tumor genetics and detect minimal residual disease.

Treatment Techniques:

Minimally Invasive Surgery:

Minimally invasive techniques, such as laparoscopy, have gained prominence in ovarian cancer surgery. They offer shorter recovery times and reduced post-operative complications.

Hyperthermic Intraperitoneal Chemotherapy (HIPEC):

HIPEC is an innovative technique that delivers heated chemotherapy directly to the abdominal cavity during surgery. This approach targets residual cancer cells and has shown promise in improving survival rates.

Browse More Information:

Clinical Assessment:

Multidisciplinary Teams:

Ovarian cancer treatment requires collaboration among various specialists, including gynecologic oncologists, surgeons, medical oncologists, and radiologists, to create personalized treatment plans.

Survivorship Care:

Long-term survivorship care plans are essential to address the physical, emotional, and psychological aspects of recovery after ovarian cancer treatment.

Expanding Therapeutic Landscape:

The ovarian cancer therapeutics market is witnessing a surge in research and development efforts, with a growing number of targeted and immunotherapeutic agents in the pipeline.

Regional Research Initiatives:

Different regions are contributing to ovarian cancer research with unique perspectives and approaches, fostering a global network of knowledge-sharing and collaboration.

Conclusion:

Ovarian cancer poses significant clinical challenges, but with advances in diagnostics, treatment modalities, and regulatory frameworks, there is hope for improved outcomes and a brighter future for those affected by this disease.

Browse Through More Oncology Diseases Research Reports.

Related Reports:

Diverticulitis: A Complete Guide to the Symptoms, Causes, and Treatments

When it comes to strategic Diabetes Disease consultancy, some of the areas we assist you understand include Regulatory Insights, Disease Landscape, and Market Access Expertise.

Find treatments for HPV illness using specialized market entry strategies. FDA/EMA insights and clinical trial advice. Examine right away!

Learn about specific approaches to Pancreatic Cancer Disease market access, pricing, and reimbursement. Learn about market research and clinical trials. Change your business immediately.

Learn about KOLs, the FDA, epidemiology, price reimbursement, and more in this market report on Anemia Disease. Your trustworthy source for info on anemia. Examine right away!

[techninja]

Hope on the Horizon: Advancements in Desmoplastic Small Round Cell Tumor Treatment Market

Introduction

Desmoplastic Small Round Cell Tumor (DSRCT) is a rare and aggressive cancer that primarily affects children, adolescents, and young adults. The treatment landscape for DSRCT has been evolving rapidly in recent years, driven by increased understanding of the disease and advancements in medical research. This article explores the latest developments in the Desmoplastic Small Round Cell Tumor treatment market, focusing on novel therapies, targeted approaches, and the overall outlook for patients.

Understanding DSRCT

DSRCT is characterized by the presence of small, round, blue cells surrounded by dense fibrous tissue, making it a challenging cancer to treat. Traditionally, treatment options for DSRCT have included a combination of surgery, chemotherapy, and radiation therapy. However, outcomes have been less than satisfactory due to the tumor's aggressive nature and resistance to conventional treatments.

Emerging Therapies

In recent years, the Desmoplastic Small Round Cell Tumor treatment market has witnessed a surge in research and development efforts, resulting in promising new therapies. Some of the notable advancements include:

1. Immunotherapy: Immunotherapy has gained significant attention in the treatment of various cancers, including DSRCT. Checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy are being explored as potential options. These therapies aim to harness the patient's immune system to target and destroy cancer cells more effectively.

2. Targeted Therapies: Researchers have identified specific molecular targets in DSRCT cells, allowing for the development of targeted therapies. Tyrosine kinase inhibitors and PARP inhibitors, for example, are showing promise in preclinical studies, disrupting the tumor's growth pathways.

3. Precision Medicine: The use of precision medicine in DSRCT treatment is gaining ground. Genomic profiling and molecular diagnostics help identify individual patient characteristics and tailor treatment plans accordingly, potentially improving response rates and reducing side effects.

4. Combined Modalities: Multi-modal treatment approaches are being explored, combining surgery, radiation therapy, and novel therapies. This comprehensive strategy aims to increase the chances of tumor shrinkage and improve overall survival rates.

Challenges in DSRCT Treatment

Despite these advancements, several challenges persist in the Desmoplastic Small Round Cell Tumor treatment market:

1. Rarity: DSRCT is an exceptionally rare cancer, making it difficult to conduct large-scale clinical trials and gather sufficient data for evidence-based treatments.

2. Resistance: DSRCT tumors often develop resistance to conventional therapies, necessitating the development of alternative treatment options.

3. Side Effects: Many of the emerging therapies may have side effects, and long-term effects are not yet fully understood.

4. High Costs: Novel therapies and precision medicine can be expensive, posing challenges in terms of accessibility and affordability for patients.

Patient Outlook

The evolving treatment landscape brings hope to DSRCT patients and their families. While a cure is not yet within reach, the increased understanding of the disease and the development of targeted therapies offer the possibility of improved survival rates and quality of life.

Furthermore, support networks and patient advocacy groups play a crucial role in raising awareness and providing valuable resources for those affected by DSRCT. These groups contribute to the ongoing research efforts and help patients access the latest information and treatment options.

Conclusion

The Desmoplastic Small Round Cell Tumor treatment market is undergoing a transformation, driven by breakthroughs in research and the development of novel therapies. While challenges persist, the future for DSRCT patients is brighter than ever. As our understanding of this rare cancer deepens and new treatment options emerge, the hope for better outcomes and improved patient quality of life continues to grow. Collaboration among researchers, healthcare professionals, patients, and advocacy groups will be key to furthering progress in the fight against DSRCT.